Literature DB >> 28621218

Measuring Disability in Patients With Cervical Dystonia According to the International Classification of Functioning, Disability and Health.

Joke De Pauw1, Kevin van der Velden1, Reen Cox1, Steven Truijen1, Patrick Cras1,2, Rudy Mercelis1,2, Willem De Hertogh1.   

Abstract

Cervical Dystonia (CD) is a rare movement disorder characterized by an abnormal head position. This cross-sectional study describes the health status and severity of disability using an internationally agreed language by applying the International Classification of Functioning, Disability and Health (ICF). Two disease-specific rating scales were administered to 30 patients with CD. By linking the individual answers to the ICF model, the frequency and severity of reported impairments and restrictions were estimated using a count-based method. Results showed that patients most frequently reported impairments linked to "neuromusculoskeletal and movement-related functions" and "mental functions." Most restrictions in activities were related to "interpersonal interactions and relations," "major life areas," and "community, social, and civic life." One third of the reported impairments can be labeled as severe disability. The findings show that CD causes disability in multiple levels of a patients' functioning in life, well beyond the cervical area.

Entities:  

Keywords:  disability; health; health-related quality of life; neurology

Mesh:

Year:  2017        PMID: 28621218     DOI: 10.1177/1539449217697043

Source DB:  PubMed          Journal:  OTJR (Thorofare N J)        ISSN: 1539-4492


  2 in total

Review 1.  Systematic Review of Rehabilitation in Focal Dystonias: Classification and Recommendations.

Authors:  Cecília N Prudente; Lena Zetterberg; Annika Bring; Lynley Bradnam; Teresa J Kimberley
Journal:  Mov Disord Clin Pract       Date:  2018-03-13

Review 2.  Neurorehabilitation in dystonia: a holistic perspective.

Authors:  Lynley V Bradnam; Rebecca M Meiring; Melani Boyce; Alana McCambridge
Journal:  J Neural Transm (Vienna)       Date:  2020-10-24       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.